Omeros’ (OMER) Buy Rating Reaffirmed at D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $36.00 target price on the biopharmaceutical company’s stock. D. Boral Capital’s price objective would suggest a potential upside of 173.45% from the stock’s current price.

Other equities research analysts have also recently issued reports about the company. HC Wainwright raised their target price on Omeros from $20.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Wall Street Zen raised Omeros from a “hold” rating to a “buy” rating in a report on Saturday. Zacks Research raised Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Omeros in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $40.33.

Omeros Stock Down 2.3%

OMER stock traded down $0.31 during mid-day trading on Tuesday, reaching $13.17. The company had a trading volume of 312,019 shares, compared to its average volume of 1,457,648. The stock has a market capitalization of $947.88 million, a P/E ratio of -26.33 and a beta of 2.53. Omeros has a one year low of $2.95 and a one year high of $17.65. The stock’s 50-day simple moving average is $11.43 and its two-hundred day simple moving average is $10.51.

Omeros (NASDAQ:OMER) last posted its earnings results on Tuesday, March 31st. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $3.69. On average, research analysts forecast that Omeros will post -1.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Farther Finance Advisors LLC increased its holdings in shares of Omeros by 16.5% during the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,004 shares during the period. State of Wyoming acquired a new position in Omeros during the fourth quarter worth about $25,000. AQR Capital Management LLC grew its holdings in Omeros by 7.2% during the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 1,532 shares during the period. ProShare Advisors LLC grew its holdings in Omeros by 12.1% during the fourth quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after acquiring an additional 1,637 shares during the period. Finally, Cerity Partners LLC grew its holdings in Omeros by 6.1% during the fourth quarter. Cerity Partners LLC now owns 30,450 shares of the biopharmaceutical company’s stock worth $523,000 after acquiring an additional 1,750 shares during the period. 48.79% of the stock is owned by institutional investors and hedge funds.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.